Francisco José Lázaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francisco José Lázaro has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Lucía Gutiérrez
Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain
18 shared publications - Maria Puerto Morales
Instituto de Ciencia de Materiales de Madrid, ICMM/CSIC, C/Sor Juana Inés de la Cruz 3, 28049 Madrid, Spain
7 shared publications - Domingo Francisco Barber
Department of Immunology and Oncology, and Nanobiomedicine Initiative, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain
4 shared publications - Raquel Mejías
Department of Biomedical Engineering, Vanderbilt University , VU Station B 351631, Nashville, Tennessee 37235-1631, United States
4 shared publications A. López
3 shared publicationsAna R. Abadía
2 shared publications
Latest Publications
- Open Access
- 1 June 2016
- Published by American Geophysical Union (AGU) in Journal of Geophysical Research: Solid Earth
- Vol. 121 (6) , 4118-4129
Detailed magnetic monitoring of the enhanced magnetism of ferrihydrite along its progressive transformation into hematite
- 1 June 2016
- Published by American Geophysical Union (AGU) in Journal of Geophysical Research: Solid Earth
- Vol. 121 (6) , 4118-4129
Open AccessDetailed magnetic monitoring of the enhanced magnetism of ferrihydrite along its progressive transformation into hematite
- 7 January 2014
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 16 (10) , 4456-4464
Prospects for magnetic nanoparticles in systemic administration: synthesis and quantitative detection
Methods for the quantitative determination of magnetic nanoparticles in biological matrices, in the frame of biomedical applications, are required to evaluate the particles biodistribution after systemic administration.
- 7 January 2014
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 16 (10) , 4456-4464
Prospects for magnetic nanoparticles in systemic administration: synthesis and quantitative detection
Methods for the quantitative determination of magnetic nanoparticles in biological matrices, in the frame of biomedical applications, are required to evaluate the particles biodistribution after systemic administration.
- 1 October 2013
- Published by Elsevier in Journal of Controlled Release
- Vol. 171 (2) , 225-233
Long term biotransformation and toxicity of dimercaptosuccinic acid-coated magnetic nanoparticles support their use in biomedical applications
- 1 October 2013
- Published by Elsevier in Journal of Controlled Release
- Vol. 171 (2) , 225-233
Long term biotransformation and toxicity of dimercaptosuccinic acid-coated magnetic nanoparticles support their use in biomedical applications
- Open Access
- 1 January 2013
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 5 (8) , 997-1005
Biophysical and genetic analysis of iron partitioning and ferritin function in Drosophila melanogaster
Metals have vital functions as prosthetic groups in enzymes, but in labile form they can propagate oxidative stress. The primary function of ferritin
- 1 January 2013
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 5 (8) , 997-1005
Open AccessBiophysical and genetic analysis of iron partitioning and ferritin function in Drosophila melanogaster
Metals have vital functions as prosthetic groups in enzymes, but in labile form they can propagate oxidative stress. The primary function of ferritin
- 21 December 2012
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Magnetics
- Vol. 49 (1) , 398-401
Effect of Anesthesia on Magnetic Nanoparticle Biodistribution After Intravenous Injection
The role of anesthesia on magnetic nanoparticle biodistribution among different organs after intravenous injection has been studied in a murine model. Animals were anesthetized by inhalation with isoflurane (0.5% in oxygen) or by intraperitoneal injection with a mixture of ketamine and xylazine. Then, monodisperse dimercaptosuccinic acid coated magnetic nanoparticles (diameter of 9.2 nm 1.2 nm) were administered intravenously to the animals. Lung and liver tissues were collected after the particle administration and the amount of particles in each tissue was determined by alternating current magnetic susceptibility measurements. Whereas the amount of particles that reaches the liver seems not to be affected by the anesthesia used, the amount of particles that reaches the lungs for inhaled isoflurane is three times less than for the intraperitoneally injected anesthetic.
- 21 December 2012
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Magnetics
- Vol. 49 (1) , 398-401
Effect of Anesthesia on Magnetic Nanoparticle Biodistribution After Intravenous Injection
The role of anesthesia on magnetic nanoparticle biodistribution among different organs after intravenous injection has been studied in a murine model. Animals were anesthetized by inhalation with isoflurane (0.5% in oxygen) or by intraperitoneal injection with a mixture of ketamine and xylazine. Then, monodisperse dimercaptosuccinic acid coated magnetic nanoparticles (diameter of 9.2 nm 1.2 nm) were administered intravenously to the animals. Lung and liver tissues were collected after the particle administration and the amount of particles in each tissue was determined by alternating current magnetic susceptibility measurements. Whereas the amount of particles that reaches the liver seems not to be affected by the anesthesia used, the amount of particles that reaches the lungs for inhaled isoflurane is three times less than for the intraperitoneally injected anesthetic.
- 20 November 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (50) , 20590-20595
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia
There is no effective treatment for the cardiomyopathy of the most common autosomal recessive ataxia, Friedreich ataxia (FA). This disease is due to decreased expression of the mitochondrial protein, frataxin, which leads to alterations in mitochondrial iron (Fe) metabolism. The identification of potentially toxic mitochondrial Fe deposits in FA suggests Fe plays a role in its pathogenesis. Studies using the muscle creatine kinase (MCK) conditional frataxin knockout mouse that mirrors the disease have demonstrated frataxin deletion alters cardiac Fe metabolism. Indeed, there are pronounced changes in Fe trafficking away from the cytosol to the mitochondrion, leading to a cytosolic Fe deficiency. Considering Fe deficiency can induce apoptosis and cell death, we examined the effect of dietary Fe supplementation, which led to body Fe loading and limited the cardiac hypertrophy in MCK mutants. Furthermore, this study indicates a unique effect of heart and skeletal muscle-specific frataxin deletion on systemic Fe metabolism. Namely, frataxin deletion induces a signaling mechanism to increase systemic Fe levels and Fe loading in tissues where frataxin expression is intact (i.e., liver, kidney, and spleen). Examining the mutant heart, native size-exclusion chromatography, transmission electron microscopy, Mössbauer spectroscopy, and magnetic susceptibility measurements demonstrated that in the absence of frataxin, mitochondria contained biomineral Fe aggregates, which were distinctly different from isolated mammalian ferritin molecules. These mitochondrial aggregates of Fe, phosphorus, and sulfur, probably contribute to the oxidative stress and pathology observed in the absence of frataxin.
- 20 November 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (50) , 20590-20595
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia
There is no effective treatment for the cardiomyopathy of the most common autosomal recessive ataxia, Friedreich ataxia (FA). This disease is due to decreased expression of the mitochondrial protein, frataxin, which leads to alterations in mitochondrial iron (Fe) metabolism. The identification of potentially toxic mitochondrial Fe deposits in FA suggests Fe plays a role in its pathogenesis. Studies using the muscle creatine kinase (MCK) conditional frataxin knockout mouse that mirrors the disease have demonstrated frataxin deletion alters cardiac Fe metabolism. Indeed, there are pronounced changes in Fe trafficking away from the cytosol to the mitochondrion, leading to a cytosolic Fe deficiency. Considering Fe deficiency can induce apoptosis and cell death, we examined the effect of dietary Fe supplementation, which led to body Fe loading and limited the cardiac hypertrophy in MCK mutants. Furthermore, this study indicates a unique effect of heart and skeletal muscle-specific frataxin deletion on systemic Fe metabolism. Namely, frataxin deletion induces a signaling mechanism to increase systemic Fe levels and Fe loading in tissues where frataxin expression is intact (i.e., liver, kidney, and spleen). Examining the mutant heart, native size-exclusion chromatography, transmission electron microscopy, Mössbauer spectroscopy, and magnetic susceptibility measurements demonstrated that in the absence of frataxin, mitochondria contained biomineral Fe aggregates, which were distinctly different from isolated mammalian ferritin molecules. These mitochondrial aggregates of Fe, phosphorus, and sulfur, probably contribute to the oxidative stress and pathology observed in the absence of frataxin.
- 1 July 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1822 (7) , 1147-1153
Quantitative magnetic analysis reveals ferritin-like iron as the most predominant iron-containing species in the murine Hfe-haemochromatosis
- 1 July 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1822 (7) , 1147-1153
Quantitative magnetic analysis reveals ferritin-like iron as the most predominant iron-containing species in the murine Hfe-haemochromatosis
- 9 February 2012
- Published by SPIE-Intl Soc Optical Eng
- Vol. 8232, 82320X-82320X-8
Fighting cancer with magnetic nanoparticles and immunotherapy
IFN-γ-adsorbed DMSA-coated magnetite nanoparticles can be used as an efficient in vivo drug delivery system for tumor immunotherapy. Magnetic nanoparticles, with adsorbed interferon-γ, were targeted to the tumor site by application of an external magnetic field. A relevant therapeutic dosage of interferon in the tumor was detected and led to a notable reduction in tumor size. In general, only 10% of the total injected nanoparticles after multiple exposures were found in tissues by AC susceptibility measurements of the corresponding resected tissues. Magnetic nanoparticle biodistribution is affected by the application of an external magnetic field.
- 9 February 2012
- Published by SPIE-Intl Soc Optical Eng
- Vol. 8232, 82320X-82320X-8
Fighting cancer with magnetic nanoparticles and immunotherapy
IFN-γ-adsorbed DMSA-coated magnetite nanoparticles can be used as an efficient in vivo drug delivery system for tumor immunotherapy. Magnetic nanoparticles, with adsorbed interferon-γ, were targeted to the tumor site by application of an external magnetic field. A relevant therapeutic dosage of interferon in the tumor was detected and led to a notable reduction in tumor size. In general, only 10% of the total injected nanoparticles after multiple exposures were found in tissues by AC susceptibility measurements of the corresponding resected tissues. Magnetic nanoparticle biodistribution is affected by the application of an external magnetic field.
- 1 April 2011
- Published by Elsevier in Biomaterials
- Vol. 32 (11) , 2938-2952
Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy
- 1 April 2011
- Published by Elsevier in Biomaterials
- Vol. 32 (11) , 2938-2952
Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy
- 2 September 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (9) , 1574-1584
Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
The serum ferritin concentration is a clinical parameter measured widely for the differential diagnosis of anemia. Its levels increase with elevations of tissue iron stores and with inflammation, but studies on cellular sources of serum ferritin as well as its subunit composition, degree of iron loading and glycosylation have given rise to conflicting results. To gain further understanding of serum ferritin, we have used traditional and modern methodologies to characterize mouse serum ferritin. We find that both splenic macrophages and proximal tubule cells of the kidney are possible cellular sources for serum ferritin and that serum ferritin is secreted by cells rather than being the product of a cytosolic leak from damaged cells. Mouse serum ferritin is composed mostly of L-subunits, whereas it contains few H-subunits and iron content is low. L-subunits of serum ferritin are frequently truncated at the C-terminus, giving rise to a characteristic 17-kD band that has been previously observed in lysosomal ferritin. Taken together with the fact that mouse serum ferritin is not detectably glycosylated, we propose that mouse serum ferritin is secreted through the nonclassical lysosomal secretory pathway.
- 2 September 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (9) , 1574-1584
Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
The serum ferritin concentration is a clinical parameter measured widely for the differential diagnosis of anemia. Its levels increase with elevations of tissue iron stores and with inflammation, but studies on cellular sources of serum ferritin as well as its subunit composition, degree of iron loading and glycosylation have given rise to conflicting results. To gain further understanding of serum ferritin, we have used traditional and modern methodologies to characterize mouse serum ferritin. We find that both splenic macrophages and proximal tubule cells of the kidney are possible cellular sources for serum ferritin and that serum ferritin is secreted by cells rather than being the product of a cytosolic leak from damaged cells. Mouse serum ferritin is composed mostly of L-subunits, whereas it contains few H-subunits and iron content is low. L-subunits of serum ferritin are frequently truncated at the C-terminus, giving rise to a characteristic 17-kD band that has been previously observed in lysosomal ferritin. Taken together with the fact that mouse serum ferritin is not detectably glycosylated, we propose that mouse serum ferritin is secreted through the nonclassical lysosomal secretory pathway.